AFMD - Earnings announcements

MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on Tuesday, December 17, at 8:30 a.m. EST / 14:30 CET to review clinical data from AFM24-102, the combination trial of its AFM24 innate cell engager ICE® with atezolizumab in non-small cell lung cancer. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/in

AFM24 combination with atezolizumab: The non-small cell lung cancer (NSCLC) EGFR wild-type (EGFRwt) cohort completed enrollment: Objective response rate (ORR) and safety data to be presented on a Company conference call on December 17, 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101): Updated clinical data from the four cohorts of the run-in phase to be presented in a poster session at ASH 2024.AFM28 monotherapy phase 1 dose-escalation study: Updated clinical data to be presented at an oral presentation at ASH 2024.Cash runway into Q4 2025: As of September 30, 2024, cash, cash equivalents and investments were €24.1 million. Based on operating and financial plans cash-runway projected

MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r

AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable patients: 1 complete response (CR), 3 partial responses (PRs) and 8 stable diseases (SDs) were reported. Objective response rate (ORR) is 23.5% (4/17) and disease control rate (DCR) is 70.6% (12/17). Median follow-up of > 7 months, 8 of 17 patients continue on treatment.The EGFR wild type (EGFRwt) cohort of treatment refractory NSCLC patients has treated 40 patients; ORR and safety data is expected in Q4 2024 Acimtamig (AFM13) combination with AlloNK® (AB-101): Enrollment for relapsed/refractory (r/r) Hodgkin Lymphoma (HL) patients in cohor

MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2024 results and corporate update on Thursday, September 5, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use linkhttps://r

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) - - AFM28 shows single agent efficacy with 2 CR/CRi and 3 stable disease (SD) in 6 patients treated at dose level of 300 mg weekly - Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells: Recruitment in cohorts 1 and 2 completed. In the first 7 treatment refractory Hodgkin Lymphoma (HL) patients, an ORR of 85.7% observed, with 4 CRs and 2 partial responses (PRs) were observed by independent read.AFM24 combination with atezolizumab: In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed che

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://regi

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 monthsObjective responses were also seen in 4 of 13 response-evaluable EGFR mutant (EGFRmut) NSCLC patients confirming the activity of AFM24 and atezolizumab in heavily pretreated NSCLC patientsIn both NSCLC cohorts, the combination therapy shows a manageable safety profileCompany to host a conference call / webcast today at 6:00 p.m. CDT / 7:00 p.m. EDT to discuss the updated data from the AFM24-102 trial MANNHEIM, Germany,

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a studyThe FDA's Fast Track designation was granted after its review of the initial efficacy data of the EGFR wild-type cohort from the AFM24-102 studyFast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical needCompany to host a conference call / webcast on June 1, 2024 at 7:00 p.m. EDT to discuss the updated data from the AFM24-102 trial MANNHEIM, Germa

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control rate of 73.3% (11/15), including 4 objective responses (1 complete and 3 partial responses)As of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and 3 of 4 responses were ongoingThe poster of the ongoing study will be presented on June 1, 2024, 9:00 a.m. – 12:00 p.m. CDTCompany to host a conference call / webcast on June 1, 2024, at 6:00 p.m. CDT / 7:00 p.m. EDT to discuss updated results and to present initial clinical efficacy data from

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and initial efficacy data from the EGFR-mutant NSCLC cohorts are expected in Q2 2024.Acimtamig (AFM13) combination with AlloNK® (AB-101) natural killer (NK) cells (LuminICE-203): Company on track to report initial efficacy and safety data in Q2 2024.AFM28: Currently enrolling patients

MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone,

MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior approval of the Company's supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 ("Common Shares") per share. The reverse stock split is expected to be effected after market close on March 8, 2024, with the Common Shares expected to begin trading on the Nasdaq Capital Market ("NASDAQ") on a post-split basis at market open on March 11, 2024 unde

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype non-small cell lung cancer (NSCLC) expansion cohort Responses observed in 4 of 15 patients, including 1 confirmed partial response (PR), 1 unconfirmed complete response (CR) awaiting confirmation, 2 unconfirmed PRs awaiting confirmation; an additional 7 of 15 patients exhibiting stable disease (SD) leading to a disease control rate of 73%Tumor shrinkage observed in 7 of 15 (47%) patientsAll patients were pretreated with and ultimately progressed while on PD-[L]1 targeting therapyThe majority of patients experienced only mild to moderate treatment-related adverse events, co

In 32 patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated at the recommended phase 2 dose level (RP2D), the objective response rate (ORR) was 97% and the complete response (CR) rate was 78%In this cohort median EFS was 9.8 months with 84% patients alive at 12 months, and median duration of response (DoR) was 8.8 monthsPatients were heavily pretreated (median of 7 prior lines), all had previously received CPIs and BV, and were refractory to their most recent line of therapyPatients received up to four cycles of therapy and the treatment was well tolerated with no instances of cytokine release syndrome (CRS), graft versus host disease (GvHD) or immune effector cell-associated

Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH 2023; provide progress update on the LuminICE-203Review clinical data for AFM24 in solid tumorsConference call/webcast on Monday, December 11, 2023 at 1:30 p.m. PST / 4:30 p.m. EST / 22:30 CET MANNHEIM, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) --  Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host a conference call on December 11 at 1:30 p.m. PST / 4:30 p.m. EST to review clinical data presented from the combination trial of acimtamig with c

Acimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1 2024.Acimtamig: Received fast-track designation for the combination of acimtamig and AlloNK®.LuminICE-203: Received encouraging feedback from the FDA on Type C meeting.AFM13-104: Oral presentation of updated data of acimtamig in combination with cord blood-derived NK cells at the American Society of Hematology (ASH) 2023 Annual Meeting.AFM24 combination with atezolizumab: On track to report data from three expansion cohorts in December 2023.AFM28: Cleared third dose cohort without dose limiting toxicities; completed enrollment in the fourth co

MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2023 results and corporate update on Tuesday, November 14, 2023. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://

AFM13 combination with AB-101 NK cells (LuminICE-203): On track to report initial efficacy and safety data in the first half 2024; Type C meeting request submitted to FDA to clarify requirements for accelerated approval.AFM24 monotherapy: Clinical activity in 7 out of 15 heavily pretreated patients with EGFRmut non-small cell lung cancer (NSCLC), including 2 confirmed partial responses.AFM24 combinations: Affimed plans to report data from the combination with atezolizumab in the fourth quarter 2023; data from combination study with SNK01 were presented at ASCO Breakthrough.AFM28: Cleared second dose cohort without dose limiting toxicities in phase 1 dose escalation study in patients with CD1

HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2023 results and corporate update on Thursday, August 10, 2023. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://

Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohortAFM24 showed clinical activity in 7 out of 15 heavily pre-treated patients with tumor reductions, including 2 confirmed partial responses and 5 patients exhibiting stable diseaseIn line with previous results, the majority of patients experienced only mild to moderate treatment-related adverse events, confirming a well-manageable safety profile in heavily pretreated patients, an important factor for combination regimensBased on the totality of data available to date, Affimed will focus clinical development of AFM24 on combination approaches, adding an EGFR

AFM24-101 phase 1/2 results in 10 patients from the non-small cell lung cancer (NSCLC) cohort demonstrated clinical activity and a well-managed safety profile in heavily pretreated patients with EGFR mutant NSCLC; updated interim analysis data of 15 patients from the NSCLC cohort will be presented at ASCO on June 3, 2023AFM24-101 phase 1/2 interim results from the colorectal cancer (CRC) cohort show AFM24 was well tolerated in heavily pretreated patients with EGFR positive CRCCompany to host a conference call / webcast on June 3, 2023 to discuss updated results with a later cutoff date and provide a strategic update on AFM24 HEIDELBERG, Germany, May 25, 2023 (GLOBE NEWSWIRE) -- Affimed N.

AFM13 combination with AB-101 NK cells: Received IND clearance from the FDA for a phase 2 clinical trial investigating the combination therapy in relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL) and peripheral T Cell Lymphoma (PTCL). Affimed expects to initiate clinical trial in Q3 2023 and report initial data in H1 2024AFM24 monotherapy: Data from non-small cell lung cancer (NSCLC) expansion cohort accepted for poster presentation; data from colorectal cancer (CRC) cohort accepted for online publication at the American Society of Clinical Oncology (ASCO) 2023 meetingAFM24 combinations: Data from the combinations with atezolizumab and SNK01 expected to be presented in H2 2023AFM28:

Phase 2 combination study of AFM13 with AB-101 in relapsed or refractory (r/r) classical Hodgkin Lymphoma (cHL) will be an open-label, multi-center, multi-cohort study with a safety run-in followed by dose optimization and expansion phasePrimary endpoints of the study are to assess the antitumor activity by objective response rate (ORR) including complete responses (CR) and partial responses (PR)Secondary endpoints of the study are to assess efficacy, durability of response (DOR), safety and tolerability, and immunogenicity of the combination therapyThe study will include an exploratory cohort of CD30-positive peripheral T-cell lymphoma (PTCL) patientsCompany to discuss investigational new d

HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use linkhttps://registe

AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meetingAFM24: Data from the three ongoing studies expected to be presented at scientific conferences in Q2 or Q3 of 2023AFM28: Clinical phase 1 study is open and recruiting; clinical trial applications now approved in four European countries including Belgium, France, Denmark and SpainAnticipated cash runway into 2025: As of December 31, 2022, cash and cash equivalents were €190.3 million HEIDELBERG, Germany, March 23, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clini

HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://regis

AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patientsPatients had a median of seven prior lines of treatment; of note, all patients failed to demonstrate objective response to immediate prior line of therapy31 Hodgkin lymphoma patients treated at the recommended phase 2 dose (RP2D) showed an objective response rate (ORR) of 97% and a complete response (CR) rate of 77%Three of four NHL patients treated at the RP2D achieved an objective response, including one CR63% of patients treated at the RP2D with at least 6 months follow-up after initial infusion (n=24) r

AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need of CD30-positive lymphoma patients through a collaboration with Artiva Biotherapeutics; an Investigational New Drug (IND) application filing is expected in H1 2023 AFM13 combination with NK cells: As of July 31, 2022 in 24 patients with CD30-positive lymphoma treated at the highest dose level of the combination treatment of AFM13 with allogeneic cord-blood derived NK cells continues to achieve a 100% overall response rate (ORR) and an improved 70.8% complete response rate (CR) AFM13 monotherapy: On track to report topline data of the regi

HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2022 results and corporate update on Tuesday, November 15, 2022. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call

Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patientsAffimed's AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patientsAB-101 is a clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived NK cell manufactured at large scale via Artiva's AlloNKTM platform as a universal ADCC-enhancing cell therapyIn preclinical studies, the combination of AFM13 and AB-101 demonstrated potent anti-tumor activityAn investigational new drug (IND) submission to the U.S. Food and Drug Administration (

HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call, please dial +1 (866) 374-5140 for U.S. callers, or +1 (404) 400-0571 for international callers, and use PIN : 54780189# approximately 15 minutes prior to the call. To access the live audio webcast

HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2022 results and corporate update on Wednesday, June 1, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference conference ID 4440407 approximately 15 minutes prior to the call. To access the live audio

Completed enrollment for AFM13-202 monotherapy study, REDIRECT, and on track to report topline data in the second half of 2022Presented interim data in December 2021 of the combination study of AFM13 with NK cells (AFM13-104), showing 100% ORR after one treatment cycle at the highest NK cell dose. Data after two treatment cycles will be presented orally at the AACR Clinical Trials Plenary session on April 10, 2022Initiated enrollment in the expansion phase of the AFM24-101 monotherapy trial at the recommended phase 2 dose (RP2D); a poster from the dose escalation will be presented at AACR on April 11, 2022Enrollment is underway in two separate phase 1/2a studies investigating AFM24 in combin

HEIDELBERG, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2021 results and corporate update on Thursday, March 31, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference conference ID 6590614 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call

For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional patient completed cycle 1 at the RP2D and was assessed with a partial response (PR)Three of 3 patients treated with two cycles in the dose escalation part of the study at the RP2D remain in CR at 6 months after start of treatmentSide effect profile shows only five instances of transient infusion-related reactions (IRR) in more than 100 AFM13 infusions with no episodes of neurotoxicity, CRS or GvHD HEIDELBERG, Germany, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-on

100% objective response rate with a 42% complete response rate in 12 patients, according to investigator assessment, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cord blood-derived natural killer (cbNK) cells/kg pre-complexed with AFM13 No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observedAffimed to host virtual investor event on December 9th to discuss the results HEIDELBERG, Germany, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced interim

HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release third quarter 2021 results on Wednesday, November 10, 2021, and host a conference call at 8:30 a.m. EST to discuss financial results and recent corporate developments. The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 6166004 approximately 15 minutes prior to the call. To access the live audio webcast of the co

AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022.AFM13 combination with NK cells: All three dose escalation cohorts are fully enrolled with no dose limiting toxicities observed; additional patients are being enrolled at the highest dose level to confirm safety and generate additional efficacy data; data update expected at a scientific conference in Q4 2021.AFM24 monotherapy: Based on current data, doses used in cohorts 5 (320 mg) and 6 (480 mg) are pharmacologically active; no classic EGFR related side effects observed to date; dose expansion phase expected to start in 2021.AFM24 combination with anti PD-L1 checkpoint inhibitor: Clinical trial

HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release second quarter 2021 results on Wednesday, September 8, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments. The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 6156773 approximately 15 minutes prior to the call. To access the live audio webcast of the c